Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 3 2Phase 2 2Phase NA 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 2Urologic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 13gallium 68 PSMA-11 8Fluorodeoxyglucose F18 5Specimen Handling 4Positron Emission Tomography Computed Tomography 42-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 4enzalutamide 3Nivolumab 3Ipilimumab 3Interleukin-2 3Biopsy 368Ga-DKFZ-PSMA-11 3pembrolizumab 2pazopanib 2lenvatinib 2bicalutamide 2atezolizumab 2aldesleukin 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2X-Rays 2Standard of Care 2Radiation 2Positron-Emission Tomography 2Paclitaxel 2Oncolytic Virotherapy 2Nephrectomy 2Metformin 2Metastasectomy 2Immunoglobulin G 2Hydroxychloroquine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Metastasectomy × Genitourinary × Clear all
NCT02210117 2026-01-07

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
104 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT03473730 2025-01-30

Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Completed
17 enrolled
Genitourinary

Carcinoma, Renal Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡